The acquisition is part of Novonesis’ growth strategy and expands its presence across the animal biosolutions value chain.
With this milestone and bringing the Feed Enzyme Alliance home, we have now full control of the animal biosolutions value chain in a growth area with great potential. We are now an even stronger partner for our customers, and better positioned to execute on our growth strategy and generate value for our shareholders, says CEO Ester Baiget.
Tina Sejersgård Fanø, Executive Vice President, Planetary Health Biosolutions, adds: By leveraging our Research & Development, application and production capabilities as well as one consolidated go-to-market model, we’ll be able to drive growth and innovation together with our customers. We look forward to welcoming our new colleagues and realize the potential of this acquisition.
For more than 25 years, Novonesis and dsm-firmenich have partnered through the Feed Enzyme Alliance to develop, manufacture, sell, and distribute animal feed and gut health enzymes to customers worldwide.
Novonesis’ primary focus has been research, development, and manufacturing while dsm-firmenich has specialized in application testing, sales and global distribution. As of today, Novonesis takes over the sales and distribution activities.
Novonesis will continue the long-term supply relationship with dsm-firmenich for their premix business.
For more information, visit www.novonesis.com
Related posts
